Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multinational, Long-term Follow-up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study

NCT05967351 is registered in ClinicalTrials.gov with Sarepta Therapeutics, Inc. as lead sponsor.

NCT NCT05967351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05967351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multinational, Long-term Follow-up Study to Evaluate Safety and Efficacy in Subjects Who Have Previously Received SRP-9001 in a Clinical Study
Lead sponsor
Sarepta Therapeutics, Inc.
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
September 27, 2023
Completion date
October 31, 2033
Enrollment
400 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy